Correlation Between Serum and CSF Concentrations of Midazolam and 1-Hydroxy-Midazolam in Critically Ill Neurosurgical Patients

被引:0
|
作者
Farrar, Julie E. [1 ]
Stefanos, Sylvia S. [2 ]
Cava, Luis [3 ]
Kiser, Tyree H. [4 ]
Mueller, Scott W. [5 ]
Neumann, Robert [3 ]
Reynolds, Paul M. [6 ]
Sherman, Deb S. [5 ]
Maclaren, Robert [4 ]
机构
[1] Univ Tennessee, Coll Pharm, 881 Madison Ave, Memphis, TN 38163 USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[5] Univ Colorado Hosp, Aurora, CO USA
[6] Rocky Mt Reg VA Med Ctr, Denver, CO USA
关键词
midazolam; cerebrospinal fluid; critical care; neurosurgery; PHARMACOKINETICS; SEDATION;
D O I
10.1177/10600280241271130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Midazolam (MZ) is commonly used in critically ill neurosurgical patients. Neuro-penetration of MZ and its metabolite, 1-hydroxy-midazolam (1-OH-MZ), is not well characterized. Objective: This study evaluated correlations between serum and cerebrospinal fluid (CSF) concentrations of MZ and 1-OH-MZ and assessed implications on patient sedation. Methods: Adults in the neurosurgical intensive care unit (ICU) with external ventricular drains receiving MZ via continuous infusion were prospectively studied. Serum and CSF samples were obtained 12-24 h and 72-96 h after initiation, and concentrations were determined in duplicate by high-performance liquid chromatography with tandem mass spectrometry. Bivariate correlation analyses used Pearson coefficient. Results: A total of 31 serum and CSF samples were obtained from 18 subjects. At sampling, mean MZ infusion rate was 3.9 +/- 4.4 mg/h, and previous 12-h cumulative dose was 51.4 +/- 78.2 mg. Mean concentrations of MZ and 1-OH-MZ in serum and CSF were similar between timepoints. Similarly, ratios of 1-OH-MZ to MZ in serum and CSF remained stable over time. Serum MZ (126.2 +/- 89.3 ng/mL) showed moderate correlation (r(2) = 0.68, P < 0.001) with serum 1-OH-MZ (17.7 +/- 17.6 ng/mL) but not CSF MZ (3.9 +/- 2.5 ng/mL; r(2) = 0.24, P = 0.005) or CSF 1-OH-MZ (2.5 +/- 0.6 ng/mL; r(2) = 0.47, P = 0.30). CSF MZ did not correlate with CSF 1-OH-MZ (r(2) = 0.003, P < 0.001). Mean serum ratio of 1-OH-MZ to MZ (0.14 +/- 0.2 ng/mL) did not correlate with CSF ratio (1.06 +/- 0.83 ng/mL; r(2) = 0.06, P = 0.19). Concentrations and ratios were unrelated to MZ infusion rate or 12-h cumulative dose. Sedation was weakly correlated with CSF 1-OH-MZ, but not with serum MZ, serum 1-OH-MZ, or CSF MZ. Conclusion and Relevance: Continuous infusions of MZ result in measurable concentrations of MZ and 1-OH-MZ in CSF; however, CSF concentrations of MZ and 1-OH-MZ poorly represent serum concentrations or dosages. Accumulation of MZ and 1-OH-MZ in serum or CSF over time was not evident. Concentrations of MZ and 1-OH-MZ do not predict sedation levels, reinforcing that pharmacodynamic assessments are warranted.
引用
收藏
页码:244 / 249
页数:6
相关论文
共 50 条
  • [21] Sedation of critically ill patients during mechanical ventilation - A comparison of propofol and midazolam
    Kress, JP
    OConnor, MF
    Pohlman, AS
    Olson, D
    Lavoie, A
    Toledano, A
    Hall, JB
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (03) : 1012 - 1018
  • [22] CONTINUOUS-INFUSION SEDATION LORAZEPAM VERSUS MIDAZOLAM IN CRITICALLY ILL PATIENTS
    Ammar, Mahmoud
    Ammar, Abdalla
    Owusu, Kent
    Siner, Jonathan
    Chess, Adam
    Johnson, Jennifer
    CRITICAL CARE MEDICINE, 2024, 52
  • [23] RENALOUTCOMES IN CRITICALLY ILL PATIENTS RECEIVING PROPOFOLOR MIDAZOLAM A PROPENSITY SCORING ANALYSIS
    Liborio, Alexandre
    Tavares, Tacyano
    Macedo, Etienne
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [24] HEPATIC METABOLISM OF MIDAZOLAM IS INHIBITED IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY
    Kirwan, C. J.
    MacPhee, I. A.
    Lee, T.
    Holt, D.
    Philips, B. J.
    INTENSIVE CARE MEDICINE, 2010, 36 : S173 - S173
  • [25] DO INFUSIONS OF MIDAZOLAM AND PROPOFOL POSE AN INFECTION RISK TO CRITICALLY ILL PATIENTS
    FARRINGTON, M
    MCGINNES, J
    MATTHEWS, I
    PARK, GR
    BRITISH JOURNAL OF ANAESTHESIA, 1994, 72 (04) : 415 - 417
  • [26] Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients
    MacLaren, R
    Sullivan, PW
    PHARMACOTHERAPY, 2005, 25 (10): : 1319 - 1328
  • [27] Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients
    Christopher John Kirwan
    Terry Lee
    David W. Holt
    R. Michael Grounds
    Iain A. M. MacPhee
    Barbara J. Philips
    Intensive Care Medicine, 2009, 35 : 1271 - 1275
  • [28] Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients
    C. J. Kirwan
    I. A. M. MacPhee
    T. Lee
    D. W. Holt
    B. J. Philips
    Intensive Care Medicine, 2012, 38 : 76 - 84
  • [29] Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients
    Kirwan, C. J.
    MacPhee, I. A. M.
    Lee, T.
    Holt, D. W.
    Philips, B. J.
    INTENSIVE CARE MEDICINE, 2012, 38 (01) : 76 - 84
  • [30] PHARMACOKINETIC INFLUENCE OF TOCILIZUMAB ON MIDAZOLAM IN CRITICALLY ILL PATIENTS WITH COVID-19
    Mefford, Breanne
    Donaldson, Chris
    Bissell, Brittany
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 114 - 114